Atorvastatin Diepoxide Lactone Impurity
✓
데이터 정확도 100%
연중무휴 과학적 지원
⬡
제품 품질에 대한 무관용 원칙

재고 위치

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* 재고 가용성에 따라 다름

Documentation

MSDS 다운로드

샘플 COA 다운로드

포함 사항: HPLC, MASS/LC-MS, 1H NMR, FT-IR, 함량, 구조 규명 보고서(SER), 그리고 제품에 따라 추가 분석 데이터가 제공됩니다.

1046118-40-4Atorvastatin Diepoxide Lactone Impurity

● 재고 있음

카탈로그 번호:VE007949
CAS 번호:1046118-40-4
분자식:C33H33FN2O6
분자량:572.62 g/mol

에 대한 추가 정보 CAS 1046118-40-4

모약물

Atorvastatin

IUPAC명

4-(4-Fluorophenyl)-6-(1-methylethyl)-N, 2-diphenyl-5-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-3, 7-dioxa-5-azatricyclo[4.1.0.02, 4] heptane-1-carboxamide

동의어

N/A

SMILES

CC(C)C12C(O1)(C3(C(N2CCC4CC(CC(=O)O4)O)(O3)C5=CC=C(C=C5)F)C6=CC=CC=C6)C(=O)NC7=CC=CC=C7

설명

It is homozygous or heterozygous familial hypercholesterolemia, mixed dyslipidemia, isolated hypertriglyceridemia, or nonfamilial hypercholesterolemia, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), very-low-density lipoprotein (VLDL-C) and triglycerides.

References

McIver, Lindsey A., and Momin S. Siddique. “Atorvastatin.” Nih.gov, StatPearls Publishing, 5 Jan. 2019, www.ncbi.nlm.nih.gov/books/NBK430779/. Ramkumar, Satish, et al. “Statin Therapy: Review of Safety and Potential Side Effects.” Acta Cardiologica Sinica, vol. 32, no. 6, Taiwan Society of Cardiology, 2016, pp. 631–39, https://doi.org/10.6515/ACS20160611A.

견적 요청

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url